Topiramate

( DrugBank: Topiramate / KEGG DRUG: Topiramate )


5 diseases
IDDisease name (Link within this page)Number of trials
6Parkinson disease4
140Dorabe syndrome2
144Lennox-Gastaut syndrome3
IDDisease name (Link within this page)Number of trials
156Rett syndrome1
193Prader-Willi syndrome3

6. Parkinson disease


Clinical trials : 2,586Drugs : 1,871 - (DrugBank : 354) / Drug target genes : 188 - Drug target pathways : 205 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

140. Dorabe syndrome


Clinical trials : 139Drugs : 49 - (DrugBank : 17) / Drug target genes : 53 - Drug target pathways : 67 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

144. Lennox-Gastaut syndrome


Clinical trials : 128Drugs : 53 - (DrugBank : 13) / Drug target genes : 50 - Drug target pathways : 62 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

156. Rett syndrome


Clinical trials : 55Drugs : 51 - (DrugBank : 22) / Drug target genes : 77 - Drug target pathways : 116 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

193. Prader-Willi syndrome


Clinical trials : 128Drugs : 94 - (DrugBank : 25) / Drug target genes : 51 - Drug target pathways : 102 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries